Last reviewed · How we verify
Comparator: placebo to pioglitazone
Comparator: placebo to pioglitazone is a Thiazolidinedione Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.
Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Comparator: placebo to pioglitazone |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Thiazolidinedione |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Pioglitazone binds to PPAR-γ, a nuclear receptor expressed primarily in adipose tissue, muscle, and liver. This activation increases insulin sensitivity by enhancing glucose uptake and reducing hepatic glucose production, thereby lowering blood glucose in patients with type 2 diabetes. The drug also has anti-inflammatory effects and may improve lipid profiles.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Headache
- Upper respiratory tract infection
Key clinical trials
- A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS) (PHASE2)
- Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease (NA)
- Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM) (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229) (PHASE3)
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED) (PHASE3)
- Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: placebo to pioglitazone CI brief — competitive landscape report
- Comparator: placebo to pioglitazone updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Comparator: placebo to pioglitazone
What is Comparator: placebo to pioglitazone?
How does Comparator: placebo to pioglitazone work?
What is Comparator: placebo to pioglitazone used for?
Who makes Comparator: placebo to pioglitazone?
What drug class is Comparator: placebo to pioglitazone in?
What development phase is Comparator: placebo to pioglitazone in?
What are the side effects of Comparator: placebo to pioglitazone?
What does Comparator: placebo to pioglitazone target?
Related
- Drug class: All Thiazolidinedione drugs
- Target: All drugs targeting PPAR-γ (Peroxisome proliferator-activated receptor gamma)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Comparator: placebo to pioglitazone vs similar drugs
- Pricing: Comparator: placebo to pioglitazone cost, discount & access